CN116602986A - 一种用于人体组织的复合制剂 - Google Patents
一种用于人体组织的复合制剂 Download PDFInfo
- Publication number
- CN116602986A CN116602986A CN202310547504.4A CN202310547504A CN116602986A CN 116602986 A CN116602986 A CN 116602986A CN 202310547504 A CN202310547504 A CN 202310547504A CN 116602986 A CN116602986 A CN 116602986A
- Authority
- CN
- China
- Prior art keywords
- chlorine
- bactericide
- composite preparation
- boric acid
- human tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000002131 composite material Substances 0.000 title claims abstract description 11
- 239000000460 chlorine Substances 0.000 claims abstract description 37
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 34
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 21
- 239000003899 bactericide agent Substances 0.000 claims abstract description 20
- 239000004327 boric acid Substances 0.000 claims abstract description 7
- 125000001309 chloro group Chemical group Cl* 0.000 claims abstract description 3
- -1 boric acid compound Chemical class 0.000 claims abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 31
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical class OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 11
- 230000003647 oxidation Effects 0.000 claims description 6
- 238000007254 oxidation reaction Methods 0.000 claims description 6
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000005660 chlorination reaction Methods 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 abstract description 15
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 210000000416 exudates and transudate Anatomy 0.000 abstract description 3
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 22
- 229910001919 chlorite Inorganic materials 0.000 description 12
- 229910052619 chlorite group Inorganic materials 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 239000004155 Chlorine dioxide Substances 0.000 description 11
- 206010052428 Wound Diseases 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 235000019398 chlorine dioxide Nutrition 0.000 description 11
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 11
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 4
- 229960002218 sodium chlorite Drugs 0.000 description 4
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 150000001642 boronic acid derivatives Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 239000003212 astringent agent Substances 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010012435 Dermatitis and eczema Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- ZALMZWWJQXBYQA-UHFFFAOYSA-N [N].[Cl] Chemical class [N].[Cl] ZALMZWWJQXBYQA-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229940077239 chlorous acid Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910021645 metal ion Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
本发明公开了一种用于人体组织的复合制剂，该复合制剂中至少包含有杀菌剂和收敛剂：其中杀菌剂为含氯杀菌剂；收敛剂选用硼酸类化合物。当使用复合制剂时将其喷涂在感染创面上，就能同时实现杀菌、消肿、收敛渗出液的功能，与现有治疗技术相比较，本发明具备对感染性创面有杀菌功能的同时减少渗出并消肿的功效。
Description
技术领域
本发明属于临床治疗材料技术领域，尤其是涉及一种用于人体组织的复合制剂。
背景技术
皮肤粘膜和其它组织的感染所形成的创面一直是临床治疗中的重要课题，抗感染与促修复也一直是临床治疗的焦点。抗感染方面临床常用治疗方法包括：外用制剂、内服药物和光疗等；创面保护方面多采用敷料（包括固体敷料和凝胶性敷料）保护创面创面，但在治疗时常常忽略创面肿胀渗出的针对性处理。临床上在面对皮肤粘膜及组织感染所形成的创面时多采用外用制剂冲洗后涂抹凝胶敷料的方法治疗，而使用有效的收敛剂治疗则较少；组织肿胀渗液多时不利于创面修复且增加感染的几率。
发明内容
本发明要解决的技术问题在于：针对上述治疗皮肤粘膜和组织感染的创面治疗时常见的不足之处，提供一种用于皮肤、粘膜和组织的复合制剂，该复合制剂中含有杀菌剂和收敛剂，旨在解决现有技术中外用制剂缺少有效的收敛剂的问题，提升治疗效率、缩短治疗时间以及预防肿胀渗出组织的感染。
为解决该问题本发明所采用的优先的技术方案如下：一种用于人体组织的复合制剂中含有杀菌剂和收敛剂：杀菌剂选用含有效氯杀菌剂中的一种或几种组合；收敛剂选用硼酸类化合物中的一种或几种组合。
为方便说明举一例案：将亚氯酸钠（NaClO2）加入水中制成亚氯酸钠溶液，加入过硫酸钠（Na2S2O8）反应生成硫酸钠（Na2SO4）和二氧化氯（ClO2），因为二氧化氯易溶于水，所以反应后制得二氧化氯溶液，加入次氯酸钠充分搅拌溶解，交替加入硼酸盐和硼酸，并调节PH值，即可制得含有亚氯酸根（ClO2 -）、次氯酸根（ClO-）、二氧化氯、硼酸根的复合制剂。
杀菌剂选择含氯杀菌剂，是因其有杀菌高效且杀菌谱广的特点。含氯杀菌剂中含有有效氯，有效氯可以杀灭病菌；有效氯反映了含氯杀菌剂杀菌能力的大小，有效氯越高则杀菌能力越强，反之则杀菌能力越弱。有效氯杀菌时有两种作用状态：a、氧化作用杀菌：含氯杀菌剂中氯是氧化态氯。氧化态指元素以较高化合价出现的状态，对于氯来说，化合价为0、+1、+3、+4、+5、+7价就是氧化态氯。氧化态氯在氧化还原反应中释放其氧化性而被还原成化合价为-1价的还原态氯，达到自然稳定状态，这一反应过程可被我们用于杀菌，所以这些氧化态氯就是能够发挥效用的有效氯；b、氯化作用杀菌：含氯杀菌剂中的氯通过与细菌上蛋白质或脂质结合，形成氮氯化合物或含氯脂质，从而干扰细胞的代谢，最后引起细菌的死亡，这部分氯也为有效氯。
上述技术方案中的例案所得溶液中亚氯酸根（ClO2 -）中的氯为正三价阳离子氯（Cl3+）是一种非常不稳定的状态，当其透过细菌外膜进入到细菌内部后会迅速夺取细菌内部遗传物质和一些酶类物质的电子，回到阴离子氯（Cl-）的稳定状态，从而实现灭杀细菌的目的；次氯酸根（ClO-）中的氯为正一价阳离子氯（Cl+）也是一种非常不稳定的状态，当其透过细菌外膜进入到细菌内部后会迅速夺取细菌内部遗传物质和一些酶类物质的电子，回到阴离子氯（Cl-）的稳定状态，从而实现灭杀细菌的目的；二氧化氯（ClO2）对细胞壁有较好的吸附性和透过性能，可有效地氧化细胞内含疏基的酶，可与半胱氨酸、色氨酸和游离脂肪酸反应，快速控制生物蛋白质的合成，使膜的渗透性增高从而实现灭杀细菌。该复合制剂中亚氯酸根、次氯酸跟和二氧化氯有协同杀菌作用，较大提升杀菌效果。
收敛剂是指通过渗透压或者本身吸附作用使组织中的水分析出，且可以吸附渗出液，从而改变皮肤粘膜表面环境和组织水肿的状态，以促使创面或感染部位更加快速恢复的物质。
硼酸类化合物是指硼酸及硼酸盐，其中硼酸盐指硼酸根与金属离子形成的盐。目前经常使用的硼酸类化合物是硼酸及硼酸钠。硼酸类化合物一般来说有相对较弱的杀菌作用（主要是通过硼酸根与细菌蛋白质中的氨基结合而发挥作用，使细菌膜上的蛋白变性从而改变通透性，造成渗透压变化达到杀灭细菌目的），但硼酸类化合物具有较强的收敛作用，可以快速吸收渗液，并减轻皮下组织水肿，在临床上常用于皮肤出现渗出性的反应时，可以通过湿敷的方法来达到消炎、消肿、清洁创面的作用，经常用于伴随有继发感染的潮红肿胀或糜烂面上，对渗液多的急性皮炎和湿疹也具有较好的疗效。
因为含氯杀菌剂有很多种，硼酸类化合物也有很多种，用这些物质制备含有效氯和收敛剂的复合制剂时会出现多种组合方案，而前述技术方案中所述例案仅是比较容易实现又有代表性的方案，所以获得本发明所述复合制剂的方案并不局限于上述优先的技术方案中的例案，须以权利要求作为依据。
当我们在使用复合制剂时将其喷涂在创面上，就能同时实现杀菌、消肿、收敛渗出液的功能。如此与现有治疗技术相比较，本发明可提升创面杀菌效率并减少渗出从而促进创面愈合。
具体实施方式
1、取1000ml纯化水，将1020mg亚氯酸钠（NaClO2）加入水中制成亚氯酸钠溶液，缓慢加入1300mg过硫酸钠（Na2S2O8）并搅拌，反应生成硫酸钠（Na2SO4）和二氧化氯（ClO2），因为二氧化氯易溶于水，所以反应后制得二氧化氯溶液，加入次氯酸钠210mg搅拌均匀，溶液有效氯约在300ppm，将30g硼酸钠和硼酸交替加入溶液中，同时检测PH值调节至7,即可制得含有亚氯酸根（ClO2 -）、次氯酸根（ClO-）、二氧化氯（ClO2）、硼酸根的有效氯为300ppm的复合制剂。
Claims (3)
1.一种用于人体组织的复合制剂，其特征在于：该复合制剂中至少含有杀菌剂和收敛剂。
2.根据权利要求1所述的一种用于人体组织的复合制剂，其特征在于：所述杀菌剂为含氯杀菌剂，包括氯以氧化作用杀菌的含氯杀菌剂和氯以氯化作用杀菌的含氯杀菌剂。
3.根据权利要求1所述的一种用于人体组织的复合制剂，其特征在于：所述收敛剂选用硼酸类化合物中的一种或几种组合；硼酸类化合物包含硼酸及硼酸盐。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310547504.4A CN116602986A (zh) | 2023-05-16 | 2023-05-16 | 一种用于人体组织的复合制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310547504.4A CN116602986A (zh) | 2023-05-16 | 2023-05-16 | 一种用于人体组织的复合制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116602986A true CN116602986A (zh) | 2023-08-18 |
Family
ID=87679278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310547504.4A Pending CN116602986A (zh) | 2023-05-16 | 2023-05-16 | 一种用于人体组织的复合制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116602986A (zh) |
-
2023
- 2023-05-16 CN CN202310547504.4A patent/CN116602986A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100858256B1 (ko) | 생리적으로 균형 잡히고, 이온화된 산성 용액 및 상처치료에의 사용 방법 | |
| EP1103264B1 (en) | Active oxygen containing solution for promoting growth of tissue cells at wound sites | |
| AU2003251547B2 (en) | Physiologically balanced, ionized, acidic solution and methodology for use in wound healing | |
| EP1799276B1 (en) | Composition for treating wounds and burns | |
| CH701627B1 (de) | Verfahren zur Herstellung einer Zusammensetzung von Hypochlorsäure und deren Anwendungen. | |
| WO2015082937A2 (en) | Composition and uses thereof | |
| KR20210154968A (ko) | 안정화된 차아염소산 용액 및 이의 의료 및 미용 용도 | |
| CN116602986A (zh) | 一种用于人体组织的复合制剂 | |
| GB2442519A (en) | Wound treatment compositions | |
| CA2926116C (en) | Wound treatment composition | |
| CN106668062A (zh) | 药物组合物、其在制备用于伤口愈合的药物中的应用、医药制剂及医药绷带 | |
| CN116672492A (zh) | 一种应用于糖尿病细菌感染创面愈合的液体敷料及其制备方法 | |
| CN116172879A (zh) | 一种用于牙齿根管治疗的复合制剂 | |
| CN111617101A (zh) | 一种幽门螺旋杆菌冲洗液及其制备方法 | |
| CN116473996A (zh) | 一种用于牙齿根管治疗的复合制剂 | |
| CN115998796A (zh) | 抗菌消炎口腔冲洗液及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |